Company intelligence / Profile preview

Chung Mei Pharmaceutical Co., Ltd.

Changhua City, Changhua, Taiwanpitdc.org.tw ↗

Ownership: Private
Development stage: Commercial

Overview

The company's investigational new drug DCB-BO1301 received FDA approval for clinical trials in March 2017 (IND 133599) for advanced melanoma treatment. The drug has shown efficacy in inhibiting B16 melanoma growth, NO production, and COX-2 activity, with synergistic effects when combined with 5-fluorouracil or Epirubicin in vitro. It's also showing efficacy in colon and breast cancer.[6][10]

Therapeutic areas: Oncology
Modalities: Small moleculesBotanical extracts
Industry: Biotech

Partnerships

Development Center for Biotechnology (DCB)Academia SinicaPharmascience (Canada)

Beyond the preview

Go deeper on Chung Mei Pharmaceutical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chung Mei Pharmaceutical Co., Ltd..

Explore the full profile